Carteolol

Routes of
administrationEye dropsATC codeLegal statusLegal status Pharmacokinetic dataBioavailability85%MetabolismLiver, active with 8-hydrocarteololElimination half-life6–8 hoursExcretionKidney (50–70%)IdentifiersCAS NumberPubChem CIDIUPHAR/BPSDrugBankChemSpiderUNIIKEGGChEBIChEMBLCompTox Dashboard (EPA)Chemical and physical dataFormulaC₁₆H₂₄N₂O₃Molar mass292.379 g·mol⁻¹3D model (JSmol)ChiralityRacemic mixture  (verify)

Carteolol is a non-selective beta blocker used to treat glaucoma. It is administered in the form of eye drops.^{[citation needed]}

Carteolol was patented in 1972 and approved for medical use in 1980.^[1]

Pharmacology

Pharmacodynamics

Carteolol is a beta blocker, or an antagonist of the β-adrenergic receptors.^[2] It is selective for the β₁-adrenergic receptor and has intrinsic sympathomimetic activity.^[2] Carteolol has also been found to act as a serotonin 5-HT_1A and 5-HT_1B receptor antagonist in addition to being a beta blocker.^[3]

Pharmacokinetics

Carteolol is classified as a beta blocker with low lipophilicity and hence lower potential for crossing the blood–brain barrier.^[2] This in turn may result in fewer effects in the central nervous system as well as a lower risk of neuropsychiatric side effects.^[2]

Society and culture

Brand names

Brand names of carteolol include Arteolol, Arteoptic, Calte, Cartéabak, Carteol, Cartéol, Cartrol, Elebloc, Endak, Glauteolol, Mikelan, Ocupress, Poenglaucol, Singlauc, and Teoptic.

References

Further reading